Third Quarter 2024 Results Key Financial Results Net loss: US$76.7m (loss ...

H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price ...

Leerink Partners analyst Thomas Smith reiterated a Buy rating on Viridian Therapeutics (VRDN – Research Report) on November 12 and set a ...

On Friday, Viridian Therapeutics Inc (VRDN) stock saw a decline, ending the day at $20.14 which represents a decrease of $-1.50 or -6.93% from the prior close of $21.64. The stock opened at $21.72 and ...

November 12, 2024--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare ...

Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of -3.60% and 4.88%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the ...

Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to loss of $1.09 per share a year ago.

Viridian Therapeutics ( (VRDN)) has issued an update. Viridian Therapeutics, a biotech company, highlights its recent advancements in treating thyroid eye disease (TED) and FcRn inhibitor ...

Mr. Myers was Chief Executive Officer, President and Director of Viridian Therapeutics, a publicly traded biotechnology company, until November 2023. He was previously Chief Executive Officer and ...

The Green Lantern and his fellow Corpsmen are some of the greatest champions of good in all of DC Comics lore, and their ...

Prevent Blindness has designated November 18 to 24, 2024, as the 5th annual Thyroid Eye Disease (TED) Awareness Week. The ...

Whether you’re exploring the Viridian Forest in the first generation Pokemon games or changing your classes in Metaphor, you ...